Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho +11 more
wiley +1 more source
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. [PDF]
Clin Transl Immunology, 2023 de Boer EC +14 more
europepmc +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond. [PDF]
Immunol Rev, 2023 Pedersen DV, Lorentzen J, Andersen GR.
europepmc +1 more source
Activation of the alternative and classical complement pathways by Entamoeba histolytica [PDF]
, 1985 J. Calderón, Robert D. Schreiber
openalex +1 more source
Diagnosis of complement alternative pathway disorders.
Kidney International, 2016 A. Angioi +8 more
semanticscholar +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
... and alternative pathways [PDF]
Nature Reviews Molecular Cell Biology, 2001 openaire +2 more sources
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. [PDF]
Immunol Rev, 2023 Risitano AM +3 more
europepmc +1 more source
Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. [PDF]
, 1986 Michael S. Krangel
openalex +1 more source